Aceril

Aceril

• Active substance: Captopril (Captopril)

• Tablets: 12.5 mg, 25 mg, 50 mg, 100 mg

• Arterial hypertension (high blood pressure).

• Chronic heart failure (as part of complex therapy).

• Diabetic nephropathy (kidney disease in diabetes mellitus).

• Left ventricular dysfunction after myocardial infarction (as part of complex therapy).

• Treatment of hypertensive crisis.

Aceril is taken orally 1 hour before meals. The dose is set by the doctor individually, depending on the severity of the disease and the patient's response to treatment.

Arterial hypertension

• Initial dose: 12.5 mg two or three times a day.

• If necessary, the dose can be gradually increased to 25 mg two or three times a day and then to 50 mg two or three times a day.

• The dose increase should not be carried out more often than once every 2 weeks.

• Maximum daily dose: 150 mg.

Chronic heart failure

• Initial dose: 6.25 mg three times a day.

• If necessary, the dose can be gradually increased to 12.5 mg three times a day, and then to 25 mg three times a day.

• The dose increase should not be carried out more often than once every 2 weeks.

• Maximum daily dose: 150 mg.

Diabetic nephropathy

• 25 mg three times daily.

Left ventricular dysfunction after myocardial infarction

• Initial dose: 6.25 mg three times a day.

• The dose can be gradually increased to 25 mg three times a day.

Hypertensive crisis

• 12.5-25 mg under the tongue.

• Hypersensitivity to captopril, other ACE inhibitors or to any other component of the drug.

• Angioedema in the history associated with the use of ACE inhibitors.

• Hereditary or idiopathic angioedema.

• Bilateral renal artery stenosis or stenosis of the sole renal artery.

• Severe renal failure.

• Severe hepatic failure.

• Primary hyperaldosteronism.

• Pregnancy and breastfeeding period.

• Age under 18 years.

• Concomitant use with aliskiren in patients with diabetes mellitus or impaired renal function (ICF < 60 ml/min/1.73 m²).

Aceril should be used with caution in patients with:

• Kidney disease (especially renal artery stenosis).

• Heart disease (e.g., coronary artery disease, heart failure).

• Diabetes mellitus.

• Autoimmune diseases (e.g., systemic lupus erythematosus, scleroderma).

• Advanced age.

Additional Precautions:

• A sharp decrease in blood pressure may occur at the beginning of treatment, especially in patients with sodium or fluid deficiency.

• During therapy it is necessary to regularly monitor renal function, electrolyte levels (potassium, sodium) and general blood analysis.

• Dry cough is possible.

• In rare cases angioedema may occur - in case of its occurrence, consult a doctor immediately.

• Use with caution in patients on hemodialysis.

• Before surgical intervention it is necessary to inform the doctor about taking captopril.

• ACE inhibitors may be less effective in patients of negroid race.

• Use in patients with aortic or mitral stenosis requires special caution.

It is not recommended to take together with:

• Potassium-saving diuretics (spironolactone, amiloride, triamterene).

• Non-steroidal anti-inflammatory drugs (NSAIDs).

• Allopurinol.

• Procainamide.

• Immunosuppressants (azathioprine, cyclophosphamide).

• Lithium preparations.

• mTOR inhibitors (sirolimus, everolimus, temsirolimus).

• Insulin and oral hypoglycemic drugs.

• Pregnancy: contraindicated. Captopril may cause teratogenic effects and serious fetal abnormalities. In pregnancy, it is necessary to discontinue use and switch to alternative therapy.

• Breast-feeding: contraindicated, as captopril penetrates into breast milk.

• Fertility: no data on the effect on fertility.

• At the beginning of treatment captopril may cause dizziness, drowsiness, visual disturbances. In the future, the degree of restrictions is determined individually.

• Very frequent (≥ 1/10): dizziness, dry cough.

• Frequently (≥ 1/100 to < 1/10): taste disturbance, rash, pruritus, orthostatic hypotension, chest pain, fatigue.

• Infrequently (≥ 1/1,000 to < 1/100): tachycardia, angioedema, vomiting, constipation, loss of appetite, sleep disturbance.

• Rarely (≥ 1/10,000 to < 1/1,000): neutropenia, agranulocytosis, pancytopenia, renal failure, proteinuria, impotence, gynecomastia.

• Very rare: Stevens-Johnson syndrome, toxic epidermal necrolysis, photosensitivity.

• Symptoms: marked decrease in blood pressure, dizziness, syncope, tachycardia, bradycardia, renal dysfunction, electrolyte imbalance.

• Treatment: intravenous administration of saline solution, vasopressors, atropine for bradycardia, adrenaline for angioedema.

• ACE inhibitor, blocks the conversion of angiotensin I to angiotensin II, dilates blood vessels, lowers blood pressure and reduces aldosterone secretion.

• Bioavailability: 60-75%.

• Binding to proteins: 25-30%.

• Excretion: via kidneys, half-life - 2 hours.

• The composition of excipients depends on the manufacturer and is specified in the instructions for use.

• It is indicated on the packaging.

• Keep out of reach of children.

• Store at a temperature not exceeding 25°C (or as directed on the package).

• Packaging form: Blisters with tablets.

• The number of tablets in the package is indicated on the package.

• Medicines should not be disposed of in sewers or household waste.

• Your pharmacist should be consulted about how to dispose of unwanted medicines to protect the environment.

• Officially registered and distributed in Israel

Dexcel Ltd (Israel).

• It is dispensed with a doctor's prescription.

• Take strictly according to the doctor's prescription.

• Do not exceed the recommended dose.

• Take 1 hour before meals.

• Regularly monitor blood pressure, renal function and electrolyte levels.

• Avoid sudden movements, especially at the beginning of therapy.

• Inform your doctor about all medications you are taking.

• If side effects occur, contact your doctor immediately.

• Women of childbearing age should use reliable contraceptive methods during treatment.

• C09AA01 - Captopril.

• I10 - Essential [primary] hypertension.

• I50 - Heart failure.

• N08 - Glomerular lesions in diseases classified in other headings.